Comparative Efficacy of Mepolizumab and Dupilumab in Eosinophilic COPD: Insights from a Matching-Adjusted Indirect Treatment Comparison
Highlight
- No statistically significant difference between mepolizumab and dupilumab in reducing moderate/severe exacerbations in eosinophilic COPD.
- Both treatments showed comparable improvements in health-related quality of life as measured by SGRQ-C.
- Matching-adjusted indirect comparison (MAIC) methodology allowed adjustment for population differences across clinical trials.
- Findings support the interchangeable clinical utility of these monoclonal antibodies targeting type 2 inflammation in COPD patients with high eosinophil counts.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.